• 공업화학
• /
• 제34권3호
• /
• pp.264-271
• /
• 2023

본 연구에서는 라우릴 알코올에 에틸렌 옥사이드 3 몰과 프로필렌 옥사이드 1 몰을 부가한 후 설페이션을 공정을 거쳐서 ASCO^Ⓡ SLES-430을 제조하였으며, 합성한 계면활성제의 구조를 FT-IR, ¹H-NMR 및 ¹³C-NMR 분석을 통하여 확인하였다. 합성한 ASCO^Ⓡ SLES-430의 임게 마이셀 농도, 정적 표면장력, 유화력, 접촉각 등의 계면 물성과 경구 독성 및 피부 자극성 등의 안정성 지표 등을 측정하였으며, SLES 계면활성제 내에 에틸렌 옥사이드가 각각 2 몰 및 3 몰 부가된 ASCO^Ⓡ SLES-226 및 ASCO^Ⓡ SLES-328 계면활성제들과 비교하였다. 특히, ASCO^Ⓡ SLES-430의 기포 생성력과 기포 안정성을 평가하여 기존 세제 제품에서 널리 사용되고 있는 ASCO^Ⓡ SLES-226과 ASCO^Ⓡ SLES-328과 비교함으로써 ASCO^Ⓡ SLES-430의 소형 빌트인 세탁기용 세제 적용 가능성을 검토하였다.

• 공업화학
• /
• 제20권2호
• /
• pp.145-153
• /
• 2009

본 연구는 투명한 섬유유연제 제조용 양이온 계면활성제인 ASCO EAQ80의 개발 완료 후 이 제품의 안전성과 관련된 평가를 받기 위하여 실시되었다. 시험은 급성 경구투여 독성시험과 유전 독성시험으로 나뉘어 진행되었으며, 랫드를 이용한 경구 단회 투여 독성시험 결과, $LD_{50}$는 5000 mg/kg를 초과하는 것으로 판단되었으며, Globally Harmonized Classification System의 기준에 의해 Category 5 또는 Unclassified로 분류되었다. 시험물질인 ASCO EAQ80의 복귀돌연변이 유발성에 대해서, 살모넬라균(TA98, TA100, TA1535, TA1537) 및 대장균(WP2uvrA (pKM101))을 이용하여 대사활성화 및 비대사활성화의 경우에서 변이원성 시험을 실시하였고, 그 결과는 모두 음성으로 판정되었다. 또한, 염색체이상 유발성 여부를 검색하기 위하여 Chinese Hamster Lung (CHL/IU) 배양세포를 이용하여 염색체이상시험을 수행하였으며, 시험물질인 ASCO EAQ80은 단시간처리법 및 연속처리법의 경우 대사활성계 적용여부에 관계없이 Chinese Hamster Lung (CHL/IU) 배양세포에 대해 염색체이상을 유발하지 않는 것으로 확인되었다.

• 대한두경부종양학회지
• /
• 제35권2호
• /
• pp.1-10
• /
• 2019

The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 31-June 4 in Chicago, drew more than 32,000 oncology specialists from around the world. The theme of 2019 ASCO conference was "Caring for Every Patient, Learning from Every Patient". Among the topics of interest covered were new approaches to surmount limited access to cancer care and the latest advances in targeted therapies for pancreatic, prostate cancers and soft tissue sarcomas. In the field of head and neck cancer, 8 oral abstracts and 75 poster abstracts were presented at this meeting. In this review, we are going to summarize the eight studies that have been presented orally. The topics are recurrent and/or metastatic head and neck squamous cell carcinoma for two abstracts (#6000, #6002), salivary duct carcinoma for one abstract (#6001), locally advanced nasopharyngeal carcinoma for two abstracts (#6003, #6004), oropharyngeal carcinoma for two abstracts (#6006, #6008), and oral cavity cancer for one abstract (#6007).

• 공업화학
• /
• 제20권5호
• /
• pp.479-485
• /
• 2009

본 연구에서는 triethanolamine-ester quaternary ammonium salt의 ASCO EQ85 양이온 계면활성제 시스템의 기본 물성을 측정하였으며, 제타 전위 측정 및 quartz crystal microbalance 실험을 통한 계면활성제 흡착량 측정으로부터 pH 조건에 따른섬유 유연력에 관하여 살펴보았다. ASCO EQ85 계면활성제의 CMC는 약 $3{\times}10^{-3}mol/L$이며, CMC에서의 표면장력은 약 40 mN/m이었다. $25^{\circ}C$에서 1 wt% 계면활성제 수용액과 n-dodecane 사이의 계면장력을 spinning drop tensiometer를 사용하여 pH에 따라 측정한 결과, pH 증가에 따라 계면장력은 약간 증가하였으나 평형에 도달하는 시간은 pH에 관계없이 거의 일정하였다. 계면활성제 흡착량은 농도에 비례하여 증가하는 경향을 보였으며, 수용액의 pH 조건에 따라 계면활성제 흡착량이 변화하였다. 계면활성제 수용액의 pH에 따라 유연력을 측정한 결과, pH 증가에 따라 양이온 계면활성제로 세정한 섬유의 마찰계수가 증가하였으며, 양이온 계면활성제 수용액의 pH가 산성 조건일 때 섬유의 유연 효과가 크다는 것을 확인할 수 있었다. 계면활성제 수용액의 거품 안정성을 측정한 결과, 수용액의 pH가 증가함에 따라 거품의 부피가 반으로 줄어드는데 걸리는 시간이 증가하고 거품 안정성이 증가하였다.

• 해양환경안전학회:학술대회논문집
• /
• 해양환경안전학회 2018년도 공동국제학술발표회
• /
• pp.84-84
• /
• 2018

• 한국화재소방학회논문지
• /
• 제24권4호
• /
• pp.27-32
• /
• 2010

최근 도시 중심의 산업화에 의한 도시 내 인구 밀도의 증가는 생활환경의 고밀화, 집적화를 초래하였다. 이에 따라 도시 내에는 다수의 인원을 수용할 수 있는 다수의 고층 건축물이 축조되고 있는 추세이다. 하지만 고층 건물은 건물의 구조적 특성에 의해 화재발생 시 수직적 통로를 통한 연기확산속도가 증가하게 되어 높은 인명피해를 야기하게 된다. 그러므로 본 연구에서는 고층건물의 제연해석을 위해 개발된 ASCOS 프로그램을 기반으로 엔탈피 보존방정식을 추가하여 에너지 전달을 고려한 제연해석 프로그램(CAU_ESCAP)을 개발하였다. CAU_ESCAP는 ASCOS의 제연해석결과와 비교를 통해 프로그램의 타당성을 검증을 하였으며, 건물 내 화재 발생에 대해 적용하여 건물 내 제연 특성을 분석하였다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권11호
• /
• pp.5477-5482
• /
• 2012

Background: The HER-2/neu gene is altered in 15-20% of breast cancer patients. Immunohistochemistry (IHC) is considered to be the most cost-effective method for HER-2 detection in many countries. Approximately 8,000 new cases of breast cancer are observed annually in Iran. The aims of this study were to conduct a systematic review of the literature on the rate of HER-2-positive breast cancer diagnosed by IHC in Iran. Methods: A systematic search of the medical literature using the Medline/PubMed, ISI and SID databases revealed articles published in the English and Persian languages evaluating HER-2-positive breast cancer in Iran. Results: From 22 studies, 3,033 patients were evaluated, of whom 1,350 were diagnosed as HER-2-positive by IHC HER-2 testing. The mean percentage of HER-2-positive patients was 44.5%, which is higher than that recorded in international statistics. Results of this meta-analysis showed a significant heterogeneity between ratios. There was a statistically significant difference between the results of pre- and post implementation of 2007 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline. IHC HER-2 testing has been performed in Iran for over 10 years. Similar to many other countries, before establishment of an infrastructure for IHC diagnostic tests, HER-2 testing was routinely performed in Iran. Our study showed that the statistics reported from Iran varied widely; for instance, the rate of HER-2-positive cases varied from 23.3% to 81.0%. Conclusions: Our results demonstrate that the lack of standardization and harmonization of this test have led to marked variations in breast cancer diagnosis in Iran.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권1호
• /
• pp.103-110
• /
• 2012

Neoadjuvant chemotherapy for resectable esophageal carcinoma has been a focus of study, but no agreement has been reached on clinical randomized controlled trials and relevant systematic evaluation. The purpose of this study was to perform a meta-analysis on published randomized controlled trials (RCTs) that compared neoadjuvant chemotherapy and surgery with surgery alone for resectable esophageal carcinoma. Medline and manual searches was conducted in PubMed, ASCO (American Society of Clinical Oncology) meeting summary, Embase, the Cochrane Library (up to October 2010), Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Database, Wanfang Database. The selection contents were to identify all published and unpublished RCTs that compared neoadjuvant chemotherapy and surgery with surgery alone for resectable esophageal carcinoma. Sixteen RCTs which included 2,594 patients were selected. The risk ratio (RR) (95% confidence interval [CI]; P value), expressed as neoadjuvant chemotherapy and surgery versus surgery alone (treatment versus control), was 1.02 (0.95, 1.10; P=0.54) for 1-year survival, 1.29 (1.13, 1.47; P=0.0001) for 3-year survival, 1.31 (1.13, 1.51; P=0.0003) for 5-year survival, 1.00 (0.95, 1.04; P= 0.85) for rate of resection and 0.89 (0.64, 1.23; P=0.48) for operative mortality. The results showed that neoadjuvant chemotherapy for resectable esophageal carcinoma can raise the overall survival rate of patients with esophageal carcinoma, but it does not affect treatment-related mortality.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권17호
• /
• pp.7695-7700
• /
• 2015

Background: HER2/neu overexpression on cell membranes of breast cancer cells is due to HER2/neu gene amplification and it is important to identify potential candidates for anti HER2 therapy with trastuzumab. IHC, FISH and CISH are standard FDA approved assays currently used to determine HER2 status in routine practice. The aim of this study was to determine HER2 gene amplification, using the CISH method in breast carcinoma samples which had IHC +2 reactions. Materials and Methods: This study was conducted from 2008-2010 using 334 consecutive breast carcinoma samples referred from local laboratories to Mehr Hospital. CISH assays were performed for all cases, and IHC tests were also done for determining efficacy and accuracy of local labs. HER2 status in local IHC tests was compared with central IHC and CISH results. Results: Of 334 breast cancer patients, 16 were negative for HER2 IHC (0, +1), 201 cases were equivocal (+2), and 31 positive (+3). Of 334 referral cases, 88 were CISH positive (26.3%) and 246 were CISH negative (73.7%). Of 201 IHC +2 cases, HER2 gene amplification was observed in 42 cases (kappa: 0.42). A 29.9% concordance was found between local IHC and central IHC. Sensitivity and specificity of local IHC were 90% and 53.8%, respectively. Conclusions: Low accuracy of IHC results in local labs was associated with the following factors: using former FDA-approved criteria for HER2 interpretation, utilizing non-validated kits, and lack of any quality assurance program. Therefore, following the new 2014 ASCO/CAP guideline and comprehensive quality assurance should be implemented to ensure accuracy of HER2 testing.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권7호
• /
• pp.3253-3258
• /
• 2012

Objective: To evaluate the efficacy and safety of whole brain radiotherapy (WBRT) plus chemotherapy versus WBRT alone for treating brain metastases (BM) from lung cancer by performing a meta-analysis based on randomized controlled trials (RCTs). Methods: The PubMed, Embase, CENTRAL, ASCO, ESMO, CBM, CNKI, and VIP databases were searched for relevant RCTs performed between January 2000 and March 2012. After quality assessment and data extraction, the meta-analysis was performed using the RevMan 5.1 software, with funnel plot evaluation of publication bias. Results: 19 RCTs involving 1,343 patients were included. The meta-analyses demonstrated that compared to WBRT alone, WBRT plus chemotherapy was more effective with regard to the objective response rate (OR = 2.30, 95% CI = 1.79 - 2.98; P < 0.001); however, the incidences of gastrointestinal reactions (RR = 3.82, 95% CI = 2.33 - 6.28, P <0.001), bone marrow suppression (RR = 5.49, 95% CI = 3.65 - 8.25, P < 0.001), thrombocytopenia (RR = 5.83, 95% CI = 0.39 - 86.59; P = 0.20), leukopenia (RR = 3.13, 95% CI = 1.77 - 5.51; P < 0.001), and neutropenia (RR = 2.75, 95% CI = 1.61 - 4.68; P < 0.001) in patients treated with WBRT plus chemotherapy were higher than with WBRT alone. There was no obvious publication bias detected. Conclusion: WBRT plus chemotherapy can obviously improve total efficacy rate, butalso increases the incidence of adverse reactions compared to WBRT alone. From the limitations of this study, more large-scale, high-quality RCTs are suggested for further verification.